SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Pluvia's Fist.com - Pluvia's Plays & Portfolio
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jane4IceCream who wrote (1758)6/26/2006 3:03:54 PM
From: Pluvia   of 1766
 
good question. 692 patients with NYHA class II CHF showed 39% reduction; this seems to be a best-in-class result. Problem is they won't have complete numbers on the breakdown until September.

I think they have a good therapeutic but their dosing is WAY, WAY to small and infrequent. Proving that means more time and money. Very frustrating as they should have done a dose ranging study by for example 2x the frequency to see if it improved results before blowing the cash on a 2400 pt study.

this being monday, i'm obviously a QB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News